I am less convinced that it is a licensing deal rather it is a clear signal to big Pharma that when they look at our website, we are focused on Onc and Onc alone and that less us go for an Onc indication to get approval first and then I’m gonna announce to them we continue to develop other indications. Or Meyer partnership comes first and they get to do it themselves.